AC Immune
AC Immune develops precision immunotherapies and diagnostics targeting misfolded proteins for neurodegenerative disease with global pharmaceutical partners.
- Public
AC Immune develops precision immunotherapies and diagnostics targeting misfolded proteins for neurodegenerative disease with global pharmaceutical partners.
acimmune.comCrawled Oct 25, 2026
AC Immune advances one of the industry’s broadest & most diverse clinical-stage pipelines focused on neurodegenerative diseases, Alzheimer's or Parkinson's
AC Immune's experienced team is pioneering precision medicine targeting neurodegeneration, and has an integrated approach to CNS-specific therapies
AC Immune’s platforms support multiple therapeutic and diagnostic approaches, expanding its pipeline of product candidates.
AC Immune advances clinical trials for its broad portfolio of precision medicine therapies targeting neurodegenerative diseases.
AC Immune describes its approach to diagnosing, treating, and preventing neurodegeneration through its latest scientific publications.
AC Immune develops breakthrough therapies for neurodegeneration using pioneering science and precision medicine.
AC Immune’s teams combines a proven track record in entrepreneurial management, World renowned scientists & Recognized leaders in neurodegenerative diseases
AC Immune partners its product candidates strategically to maximize shareholder value while managing risk.
AC Immune is a clinical-stage biopharmaceutical company & a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases
Pioneering Precision Medicine | AC Immune works with suppliers offering a high standard of service & products as well as demonstrating ethics and integrity
AC Immune SA develops precision medicine for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, using advanced technology platforms.
AC Immune designs vaccine strategies to prevent Alzheimer’s and Parkinson’s diseases.
Targeting misfolded self-proteins pioneering precision medicine for neurodegenerative diseases: Alzheimer's disease & Parkinson's disease | AC Immune SA
AC Immune’s experimental immunotherapy **ACI-7104** secures FDA Fast Track designation for early Parkinson’s disease. The decision follows promising interim clinical trial results, positioning the treatment as a potential first disease-modifying therapy for patients. The drug targets alpha-synuclein, a protein linked to Parkinson’s progression.
Aug 2026biopharminternational.comNews article
AC Immune reports progress in its pipeline, with near-term clinical catalysts for wholly-owned programs and milestone payments from partnered initiatives. The company’s Phase 2 VacSYn trial of **ACI-7104** for Parkinson’s disease receives a **$4 million grant** from The Vijay and Marie Goradia Charitable Foundation. Additionally, its **Morphomer small molecule program** targeting intracellular Tau advances, with further clinical results expected in the second half of 2026.
Aug 2026Yahoo FinanceNews article
AC Immune SA announces that CEO Dr. Andrea Pfeifer will retire at the upcoming Annual General Meeting (AGM). The company provides updates for stockholders, investors, and financial analysts through its Investor Relations platform.
May 2026AC Immune SANews article
Genentech returns two Alzheimer’s disease drug candidates to AC Immune, terminating an 18-year collaboration following clinical setbacks. The assets were originally developed under the partnership but failed to meet efficacy or safety milestones in trials. AC Immune retains full rights to the programs, marking the end of a long-standing alliance between the two companies.
Jan 2024Fierce BiotechNews article